Search

Displaying results 2861 - 2870 of 4859 in total
  1. Drug

    Lomustine

    go.drugbank.com/drugs/DB01206
    ApprovedInvestigational

    An alkylating agent of value against both hematologic malignancies and solid tumors.

  2. Drug

    Naloxone

    go.drugbank.com/drugs/DB01183
    ApprovedInvestigationalVet approved

    [A234594] More specifically, naloxone has a high affinity for μ-opioid receptors, where it acts as an inverse agonist, causing the rapid removal of any other drugs bound to these receptors.

  3. Drug

    Benzimate

    go.drugbank.com/drugs/DB05170
    Experimental

    It is currently under investigation by AmpliMed and is in phase I of clinical trial.

  4. Drug

    Pirlindole

    go.drugbank.com/drugs/DB09244
    Experimental

    It was developed and is currently used as an antidepressant in Russia. Its chemical structure is similar to metralindole, and it also shares pharmacological properties with this drug.

  5. Drug

    Corifollitropin alfa

    go.drugbank.com/drugs/DB09066
    ApprovedInvestigational

    This means that it is made by cells into which a DNA has been introduced that makes them able to produce corifollitropin alfa [L2270].

  6. Drug

    Omaveloxolone

    go.drugbank.com/drugs/DB12513
    ApprovedInvestigational

    Omaveloxolone (RTA-408) is a semisynthetic oleanane triterpenoid with antioxidant and anti-inflammatory properties. Omaveloxolone acts as an activator of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcription factor that mit...

  7. Drug

    Simotaxel

    go.drugbank.com/drugs/DB15384
    Investigational

    Simotaxel is under investigation in clinical trial NCT00088647 (Study Evaluating MST-997 in Advanced Malignant Solid Tumors).

  8. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine.

  9. Drug

    Adenosine phosphate

    go.drugbank.com/drugs/DB00131
    ApprovedInvestigationalNutraceuticalWithdrawn

    Adenosine phosphate was withdrawn by the FDA since it was considered neither safe nor effective for its intended uses as a vasodilator and an anti-inflammatory.[L43937]

  10. Drug

    Lumiracoxib

    go.drugbank.com/drugs/DB01283
    ApprovedWithdrawn

    On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver